What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance?: An analysis of the CaPSURE™ database

被引:117
作者
Barocas, Daniel A. [2 ]
Cowan, Janet E. [1 ]
Smith, Joseph A. [2 ]
Carroll, Peter R. [1 ]
机构
[1] Univ Calif San Francisco, UCSF Mt Zion Comprehens Canc Ctr, Urol Outcomes Res Grp, Program Urol Oncol,Dept Urol, San Francisco, CA 94115 USA
[2] Vanderbilt Univ, Med Ctr, Dept Urol Surg, Nashville, TN USA
关键词
prostatic neoplasms; risk assessment; disease management;
D O I
10.1016/j.juro.2008.06.019
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Active surveillance is an option for men with clinically localized prostate cancer and may be suitable for those with very low risk disease. We determined the percentage of men in a large prostate cancer registry who met criteria predictive of latent prostate cancer. We also assessed the percentage of men meeting these criteria who chose surveillance. Materials and Methods: We conducted an observational study of 1,886 men diagnosed with clinically localized prostate cancer between 1999 and 2004 from the CaPSURE database. Outcomes were percent of men meeting Epstein surveillance criteria (prostate specific antigen less than 10 ng/ml, clinical T1 or T2a, prostate specific antigen density less than 0.15, fewer than 1 of 3 biopsy cores positive, and absence of Gleason pattern 4 and 5 on biopsy) and percent selecting surveillance stratified by risk group. Results: Of 1,886 men with all 5 criteria documented 16.4% (310 of 1,886) met all 5 surveillance criteria and 9.0% (28 of 310) of men in this very low risk category actually chose surveillance compared with 4.3% (68 of 1,576) of patients in other risk groups (p <0.01). On multivariable analysis of the entire cohort older age was the only demographic predictor of surveillance. Being in the very low risk group was also a predictor of surveillance. Conclusions: Of men presenting with localized prostate cancer 16% met the criteria for very low risk disease. However, only a small subset of eligible men chose active surveillance, suggesting that it may be underused in the management of very low risk prostate cancer.
引用
收藏
页码:1330 / 1334
页数:5
相关论文
共 20 条
[1]  
Abbas A, 1996, EUR UROL, V30, P322
[2]   20-year outcomes following conservative management of clinically localized prostate cancer [J].
Albertsen, PC ;
Hanley, JA ;
Fine, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (17) :2095-2101
[3]   Radical prostatectomy versus watchful waiting in early prostate cancer [J].
Bill-Axelson, A ;
Holmberg, L ;
Ruutu, M ;
Häggman, M ;
Andersson, SO ;
Bratell, S ;
Spångberg, A ;
Busch, C ;
Nordling, S ;
Garmo, H ;
Palmgren, J ;
Adami, HO ;
Norlén, BJ ;
Johansson, JE .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (19) :1977-1984
[4]   Expectant management of nonpalpable prostate cancer with curative intent: Preliminary results [J].
Carter, HB ;
Walsh, PC ;
Landis, P ;
Epstein, JI .
JOURNAL OF UROLOGY, 2002, 167 (03) :1231-1234
[5]   Prospective evaluation of men with stage T1c adenocarcinoma of the prostate [J].
Carter, HB ;
Sauvageot, J ;
Walsh, PC ;
Epstein, JI .
JOURNAL OF UROLOGY, 1997, 157 (06) :2206-2209
[6]   The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management [J].
Cooperberg, MR ;
Lubeck, DP ;
Meni, MV ;
Mehta, SS ;
Carroll, PR .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) :2141-2149
[7]   Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer [J].
D'Amico, AV ;
Whittington, R ;
Malkowicz, SB ;
Schultz, D ;
Blank, K ;
Broderick, GA ;
Tomaszewski, JE ;
Renshaw, AA ;
Kaplan, I ;
Beard, CJ ;
Wein, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11) :969-974
[8]   PATHOLOGICAL AND CLINICAL FINDINGS TO PREDICT TUMOR EXTENT OF NONPALPABLE (STAGE-T1C) PROSTATE-CANCER [J].
EPSTEIN, JI ;
WALSH, PC ;
CARMICHAEL, M ;
BRENDLER, CB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (05) :368-374
[9]   Who is the average patient presenting with prostate cancer? [J].
Greene, KL ;
Cowan, JE ;
Cooperberg, MR ;
Meng, MV ;
DuChane, J ;
Carroll, PR .
UROLOGY, 2005, 66 (5A) :76-82
[10]  
GUILEYARDO JM, 1980, J NATL CANCER I, V65, P311